<DOC>
	<DOCNO>NCT00811850</DOCNO>
	<brief_summary>A 10 week evaluation , crossover design study include 3 week washout period treatment , determine effect Combigan® ( fix combination brimonidine tartrate 0.2 % /timolol maleate 0.5 % ) Cosopt® ( fix combination dorzolamide hydrochloride-timolol maleate ophthalmic solution ) ocular blood flow measure retrobulbar blood flow .</brief_summary>
	<brief_title>Comparing Effects Two Fixed Combinations Ophthalmic Solutions Ocular Blood Flow</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Brimonidine Tartrate , Timolol Maleate Drug Combination</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Age : 30 year old . 2 . Primary openangle glaucoma ( POAG ) ocular hypertensive least one eye . 3 . Best correct visual acuity least 20/40 least one eye . 1 . History acute angleclosure narrow , occludable anterior chamber angle gonioscopy . 2 . History chronic recurrent inflammatory eye disease ( e.g. , scleritis , uveitis ) . 3 . History sign intraocular trauma . 4 . Any abnormality prevent reliable applanation tonometry . 5 . Current use ophthalmic systemic steroid may interfere investigation . 6 . Severe , unstable uncontrolled cardiovascular , renal , pulmonary disease .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>